360 degree perspective on allergic rhinitis management in Italy: a survey of GPs, pharmacists and patients

Clinical and Molecular Allergy

GianEnrico Senna³  Massimo Triggiani²  G. Walter Canonica¹ 

[1] Respiratory and Allergy Clinic, DIMI-Department of Internal Medicine, University of Genoa, IRCCS Aou San Martino, Largo Rosanna Benzi 10, Genoa, 16132, Italy;Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy;Allergy Unit, University Hospital Verona, Verona, Italy

关键词: Survey;    Treatment;    Patient;    Pharmacist;    Physician;    Italy;    Burden;    Allergic rhinitis;   

Others  :  1230348
DOI  :  10.1186/s12948-015-0029-5

 received in 2015-05-19, accepted in 2015-08-10,  发布年份 2015

【 摘 要 】

Background

General practitioners (GPs), community pharmacists and allergic rhinitis (AR) patients in Italy were surveyed in order to gain insight from all three perspectives into the diagnosis, management and burden of AR in Italy.

Methods

General practitioners and pharmacists (n = 100 for each) were surveyed by telephone; questions related to overall practice and to last AR patient seen. Patients (n = 552) completed a questionnaire after visiting specialist allergy centres. Questions related to diagnosis and treatment, degree of everyday limitation from AR, and satisfaction with treatment. The data were analysed descriptively.

Results

Allergic rhinitis was managed mainly by GPs, who reported making the diagnosis themselves in 68 % of cases; rhinorrhea (64 %), sneezing (57 %) and congestion (49 %) were the symptoms most frequently taken into account. Limitation from AR on everyday life was rated 6.2 out of 10 by GPs. Pharmacists most often considered eye tearing (54 %) in their diagnosis. Almost half of GPs (49 %) and 87 % of pharmacists were unaware of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines. The most commonly reported prescribed treatments by GPs were branded mometasone furoate, desloratadine, ebastine and generic mometasone; 21 % prescribed homeopathic products occasionally. On average, GPs remembered that their last patient case had moderate/severe disease, was prescribed anti-histamine monotherapy (37 % of cases), and did not change prescription (78 %). Pharmacists recommended an antihistamine for 56 % of clients who asked for advice, and a nasal decongestant for 21 %. Patients rated limitation from AR on everyday life as 5.7/10. 55 % reported using multiple therapies, and 43 % were not satisfied or weakly satisfied with their current treatment. Patients’ main expectation for the future was to succeed in managing their AR symptoms (45 %), while 22 % hoped for a definitive cure. Many patients (61 %) were concerned their health would deteriorate.

Conclusions

Allergic rhinitis is largely managed by GPs in Italy, with pharmacists also playing a role, yet awareness of the ARIA guidelines among these groups is low. Patient satisfaction with treatment is moderate or low. New more effective treatments are needed to improve AR management in Italy. Allergy education programs need to be better targeted to GPs and pharmacists, and communication with patients regarding symptom control must be improved.

【 授权许可】

   
2015 Canonica et al.

【 图 表 】

Fig.1.

Fig.2.

Fig.3.

Fig.4.

Fig.5.

【 参考文献 】

• [1]Lamb CE, Ratner PH, Johnson CE, Ambegaonkar AJ, Joshi AV, Day D et al.. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin. 2006; 22(6):1203-1210.
• [2]Zanolin ME, Pattaro C, Corsico A, Bugiani M, Carrozzi L, Casali L et al.. The role of climate on the geographic variability of asthma, allergic rhinitis and respiratory symptoms: results from the Italian study of asthma in young adults. Allergy. 2004; 59(3):306-314.
• [3]Bugiani M, Carosso A, Migliore E, Piccioni P, Corsico A, Olivieri M et al.. Allergic rhinitis and asthma comorbidity in a survey of young adults in Italy. Allergy. 2005; 60(2):165-170.
• [4]Italian National Institute of Statistics. 2011. Accessed Mar 2015.
• [5]Vuurman EF, Vuurman LL, Lutgens I, Kremer B. Allergic rhinitis is a risk factor for traffic safety. Allergy. 2014; 69(7):906-912.
• [6]Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al.. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 Suppl 86:8-160.
• [7]Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB et al.. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126(3):466-476.
• [8]Demoly P, Calderon MA, Casale T, Scadding G, Annesi-Maesano I, Braun JJ et al.. Assessment of disease control in allergic rhinitis. Clin Transl Allergy. 2013; 3(1):7. BioMed Central Full Text
• [9]Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007; 62 Suppl 85:17-25.
• [10]Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy. 2007; 62 Suppl 85:9-16.
• [11]Mosges R, Klimek L. Today’s allergic rhinitis patients are different: new factors that may play a role. Allergy. 2007; 62(9):969-975.
• [12]Valovirta E, Myrseth SE, Palkonen S. The voice of the patients: allergic rhinitis is not a trivial disease. Curr Opin Allergy Clin Immunol. 2008; 8:1-9.
• [13]Bousquet PJ, Castelli C, Daures JP, Heinrich J, Hooper R, Sunyer J et al.. Assessment of allergen sensitization in a general population-based survey (European Community Respiratory Health Survey I). Ann Epidemiol. 2010; 20(11):797-803.
• [14]Settipane RA, Lieberman P. Update on nonallergic rhinitis. Ann Allergy Asthma Immunol. 2001; 86(5):494-507.
• [15]Pitman R, Paracha N, Parker C, Acaster S, Bachert C, Bousquet J. Episode pattern and healthcare utilisation in patients with seasonal allergic rhinitis. Allergy. 2012; 67 Suppl 96:1-687.
• [16]Acaster S, Shehzed A, Breheny K, Bachert C, Bousquet J, Price D. Treatment preferences in patients with moderate/severe seasonal allergic rhinitis: findings of a discrete choice experiment. Allergy. 2012; 67 Suppl 96:344.
• [17]Price D, Bousquet J, Pitman D, Lieberman P, Munzel U, Meltzer E. Sub-optimal control of allergic rhinitis: the need for a new and more effective treatment option. Allergy. 2013; 68 Suppl 97:1-744.
• [18]Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol. 2013; 160(4):393-400.
• [19]Zicari AM, Indinnimeo L, De Castro G, Incorvaia C, Frati F, Dell’Albani I et al.. A survey on features of allergic rhinitis in children. Curr Med Res Opin. 2013; 29(5):415-420.
• [20]Canonica GW, Mullol J, Pradalier A, Didier A. Patient perceptions of allergic rhinitis and quality of life: findings from a survey conducted in Europe and the United States. World Allergy Organ J. 2008; 1(9):138-144.
• [21]de Marco R, Cappa V, Accordini S, Rava M, Antonicelli L, Bortolami O et al.. Trends in the prevalence of asthma and allergic rhinitis in Italy between 1991 and 2010. Eur Respir J. 2012; 39(4):883-892.
• [22]MotA Workshops. ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma. Allergy. 2004; 59(4):373-387.
• [23]Bousquet J, Reid J, van Weel C, Baena Cagnani C, Canonica GW, Demoly P et al.. Allergic rhinitis management pocket reference 2008. Allergy. 2008; 63(8):990-996.
• [24]Anolik R. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008; 100(3):264-271.
• [25]Esteitie R, deTineo M, Naclerio RM, Baroody FM. Effect of the addition of montelukast to fluticasone propionate for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2010; 105(2):155-161.
• [26]Derendorf H, Munzel U, Petzold U, Maus J, Mascher H, Hermann R et al.. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol. 2012; 74(1):125-133.
• [27]Dymista® Nasal Spray Summary of Product Characteristics. Last updated on eMC 13-Jan-2015. http://www.medicines.org.uk/emc/medicine/27579. 2015. Accessed 3 Aug 2015.
• [28]Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW et al.. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013; 161(4):369-377.
• [29]Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D et al.. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012; 129(5):1282-1289.
• [30]Price D, Shah S, Bhatia S, Bachert C, Berger W, Bousquet J et al.. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013; 23(7):495-503.
• [31]Klimek L, Grevers G. Pharmacotherapy and diagnosis of allergic rhinitis. MMW Fortschritte der Medizin. 2014; 156(4):48-52.
• [32]Bousquet J, Bachert C, Price D, Acaster S, Demoly P. Assessing allergic rhinitis symptom control using a simple visual analogue scale: the digital solution (MACVIA-ARIA). Allergy. 2014; 69 Suppl 99:1-646.